Skip to main content
Erschienen in: Tumor Biology 3/2016

08.10.2015 | Original Article

Prognostic value of preoperative serum gamma-glutamyltranspeptidase in patients with hepatocellular carcinoma after hepatectomy

verfasst von: Shunjun Fu, Zhiyong Guo, Shaoqiang Li, Ming Kuang, Wenjie Hu, Yunpeng Hua, Xiaoshun He, Baogang Peng

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Gamma-glutamyltranspeptidase (γ-GGT), an oxidative stress marker, is correlated with inflammation in the extracellular hepatic microenvironment. This study aimed to evaluate the prognostic value of serum γ-GGT levels in patients with hepatocellular carcinoma (HCC) after hepatectomy. Three hundred and eight patients who underwent hepatic resection for HCC were included in the study. Preoperative serum γ-GGT levels, as well as demographic, clinical, and pathologic data, were analyzed. The optimal cutoff value of γ-GGT was 88 U/L. All patients were divided into γ-GGT ≤ 88 U/L group (n = 146) and γ-GGT > 88 U/L group (n = 162). The disease-free survival (DFS) and overall survival (OS) rates of patients in the γ-GGT > 88 U/L group were poorer than those in γ-GGT ≤ 88 U/L group. Preoperative serum γ-GGT levels, associating with gender, HBsAg status, tumor size, capsulation, tumor number, and vascular invasion, was an independent prognostic predictor of disease-free survival [hazard ratio (HR) = 1.616; 95 % confidence interval (CI), 1.223–2.135; P = 0.001] and overall survival (HR = 2.043; 95 % CI, 1.509–2.766; P < 0.001). Furthermore, γ-GGT was also associated with DFS and OS in small HCC (tumor size ≤5 cm) and alpha-fetoprotein (AFP) ≤ 200 ng/mL subgroup. In conclusion, γ-GGT is a promising and reliable prognostic biomarker in HCC patients after hepatic resection, especially for patients with small HCC or AFP ≤ 200 ng/mL.
Literatur
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:68–90.CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:68–90.CrossRef
3.
Zurück zum Zitat Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, Fan ST. Survival analysis of patients with transplantable recurrent hepatocellularcarcinoma: implications for salvage liver transplant. Arch Surg. 2008;143:68–74.CrossRefPubMed Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, Fan ST. Survival analysis of patients with transplantable recurrent hepatocellularcarcinoma: implications for salvage liver transplant. Arch Surg. 2008;143:68–74.CrossRefPubMed
5.
Zurück zum Zitat Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79–86.CrossRefPubMed Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79–86.CrossRefPubMed
6.
Zurück zum Zitat Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408–25.CrossRefPubMed Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408–25.CrossRefPubMed
7.
Zurück zum Zitat Pankiv S, Møller S, Bjørkøy G, Moens U, Huseby NE. Radiation-induced upregulation of gamma-glutamyltransferase in colon carcinoma cells is mediated through the Ras signal transduction pathway. Biochim Biophys Acta. 2006;1760:151–7.CrossRefPubMed Pankiv S, Møller S, Bjørkøy G, Moens U, Huseby NE. Radiation-induced upregulation of gamma-glutamyltransferase in colon carcinoma cells is mediated through the Ras signal transduction pathway. Biochim Biophys Acta. 2006;1760:151–7.CrossRefPubMed
9.
Zurück zum Zitat Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169–82.PubMed Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169–82.PubMed
10.
Zurück zum Zitat Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787–93.CrossRefPubMed Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787–93.CrossRefPubMed
11.
Zurück zum Zitat Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102–8.CrossRefPubMed Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102–8.CrossRefPubMed
12.
Zurück zum Zitat Ma H, Zhang L, Tang B, Wang Y, Chen R, Zhang B, et al. γ-Glutamyl-transpeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3084–9.CrossRefPubMed Ma H, Zhang L, Tang B, Wang Y, Chen R, Zhang B, et al. γ-Glutamyl-transpeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3084–9.CrossRefPubMed
13.
Zurück zum Zitat Hanigan MH, Frierson Jr HF. Immunohistochemical detection of gamma-glutamyltranspeptidase in normal human tissue. J Histochem Cytochem. 1996;44:1101–8.CrossRefPubMed Hanigan MH, Frierson Jr HF. Immunohistochemical detection of gamma-glutamyltranspeptidase in normal human tissue. J Histochem Cytochem. 1996;44:1101–8.CrossRefPubMed
14.
Zurück zum Zitat Hanigan MH, Frierson Jr HF, Swanson PE, De Young BR. Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol. 1999;30:300–5.CrossRefPubMed Hanigan MH, Frierson Jr HF, Swanson PE, De Young BR. Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol. 1999;30:300–5.CrossRefPubMed
15.
Zurück zum Zitat Pompella A, De Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231–8.CrossRefPubMed Pompella A, De Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231–8.CrossRefPubMed
16.
Zurück zum Zitat Roomi MW, Gaal K, Yuan QX, French BA, Fu P, Bardag-Gorce F, et al. Preneoplastic liver cell foci expansion induced by thioacetamide toxicity in drug-primed mice. Exp Mol Pathol. 2006;81:8–14.CrossRefPubMed Roomi MW, Gaal K, Yuan QX, French BA, Fu P, Bardag-Gorce F, et al. Preneoplastic liver cell foci expansion induced by thioacetamide toxicity in drug-primed mice. Exp Mol Pathol. 2006;81:8–14.CrossRefPubMed
17.
Zurück zum Zitat Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al. Prognostic value of preoperative peripheral neutrophilto-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013;30:721.CrossRefPubMed Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al. Prognostic value of preoperative peripheral neutrophilto-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013;30:721.CrossRefPubMed
18.
Zurück zum Zitat Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21:3802–9.CrossRefPubMed Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21:3802–9.CrossRefPubMed
19.
Zurück zum Zitat Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepato-Biliary-Pancreat Surg. 1998;5:7–13.CrossRef Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepato-Biliary-Pancreat Surg. 1998;5:7–13.CrossRef
20.
Zurück zum Zitat Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–53.PubMed Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–53.PubMed
21.
Zurück zum Zitat Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.CrossRefPubMed Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.CrossRefPubMed
22.
Zurück zum Zitat Borud O, Mortensen B, Mikkelsen IM, Leroy P, Wellman M, Huseby NE. Regulation of gamma-glutamyltransferase in cisplatin-resistant and -sensitive colon carcinoma cells after acute cisplatin and oxidative stress exposures. Int J Cancer. 2000;88:464–8.CrossRefPubMed Borud O, Mortensen B, Mikkelsen IM, Leroy P, Wellman M, Huseby NE. Regulation of gamma-glutamyltransferase in cisplatin-resistant and -sensitive colon carcinoma cells after acute cisplatin and oxidative stress exposures. Int J Cancer. 2000;88:464–8.CrossRefPubMed
23.
Zurück zum Zitat Mikkelsen IM, Huseby NE, Visvikis A, Moens U. Activation of the gamma-glutamyltransferase promoter 2 in the rat colon carcinoma cell line CC531 by histone deacetylase inhibitors is mediated through the Sp1-binding motif. Biochem Pharmacol. 2002;64:307–15.CrossRefPubMed Mikkelsen IM, Huseby NE, Visvikis A, Moens U. Activation of the gamma-glutamyltransferase promoter 2 in the rat colon carcinoma cell line CC531 by histone deacetylase inhibitors is mediated through the Sp1-binding motif. Biochem Pharmacol. 2002;64:307–15.CrossRefPubMed
24.
Zurück zum Zitat Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358:1–3.CrossRefPubMed Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358:1–3.CrossRefPubMed
25.
Zurück zum Zitat Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM. Differential regulation of gammaglutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta. 2001;1568:67–73.CrossRefPubMed Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM. Differential regulation of gammaglutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta. 2001;1568:67–73.CrossRefPubMed
26.
Zurück zum Zitat Bouman L, Sanceau J, Rouillard D, Bauvois B. Gammaglutamyl transpeptidase expression in Ewing’s sarcoma cells: up-regulation by interferons. Biochem J. 2002;364:719–24.CrossRefPubMedPubMedCentral Bouman L, Sanceau J, Rouillard D, Bauvois B. Gammaglutamyl transpeptidase expression in Ewing’s sarcoma cells: up-regulation by interferons. Biochem J. 2002;364:719–24.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314–8.CrossRefPubMed Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314–8.CrossRefPubMed
28.
Zurück zum Zitat Everhart JE, Wright EC. Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57:1725–33.CrossRefPubMedPubMedCentral Everhart JE, Wright EC. Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57:1725–33.CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic value of preoperative serum gamma-glutamyltranspeptidase in patients with hepatocellular carcinoma after hepatectomy
verfasst von
Shunjun Fu
Zhiyong Guo
Shaoqiang Li
Ming Kuang
Wenjie Hu
Yunpeng Hua
Xiaoshun He
Baogang Peng
Publikationsdatum
08.10.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4136-1

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.